Adeno-associated Virus Vectors: Potential Applications for Cancer Gene Therapy

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2005 Jun 18

PMID 15962012

Citations 44

Authors

Chengwen Li

Dawn E Bowles

Terry Van Dyke

Richard Jude Samulski

Affiliations

Soon will be listed here.

Abstract

Augmenting cancer treatment by protein and gene delivery continues to gain momentum based on success in animal models. The primary hurdle of fully exploiting the arsenal of molecular targets and therapeutic transgenes continues to be efficient delivery. Vectors based on adeno-associated virus (AAV) are of particular interest as they are capable of inducing transgene expression in a broad range of tissues for a relatively long time without stimulation of a cell-mediated immune response. Perhaps the most important attribute of AAV vectors is their safety profile in phase I clinical trials ranging from CF to Parkinson's disease. The utility of AAV vectors as a gene delivery agent in cancer therapy is showing promise in preclinical studies. In this review, we will focus on the basic biology of AAV as well as recent progress in the use of this vector in cancer gene therapy.

Citing Articles

Cell and gene therapy in neuro-oncology.

Varela M, Comba A, Faisal S, Argento A, Pena Aguelo J, Candolfi M Handb Clin Neurol. 2024; 205:297-315.

PMID: 39341660 PMC: 11441620. DOI: 10.1016/B978-0-323-90120-8.00009-5.

Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno-associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation.

Xie M, Wang L, Deng Y, Ma K, Yin H, Zhang X J Ophthalmol. 2024; 2024:5487973.

PMID: 39286553 PMC: 11405113. DOI: 10.1155/2024/5487973.

Fine-tuning-based Transfer Learning for Characterization of Adeno-Associated Virus.

Khan A, Kim M, Dutta P J Signal Process Syst. 2023; 94(12):1515-1529.

PMID: 36742147 PMC: 9897492. DOI: 10.1007/s11265-022-01758-3.

Gene Therapy for High Grade Glioma: The Clinical Experience.

Varela M, Comba A, Faisal S, Argento A, Franson A, Barissi M Expert Opin Biol Ther. 2022; 23(2):145-161.

PMID: 36510843 PMC: 9998375. DOI: 10.1080/14712598.2022.2157718.

Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder.

Markouli M, Ullah F, Omar N, Apostolopoulou A, Dhillon P, Diamantopoulos P Cancers (Basel). 2022; 14(23).

PMID: 36497432 PMC: 9740763. DOI: 10.3390/cancers14235949.

References

Melo L, Agrawal R, Zhang L, Rezvani M, Mangi A, Ehsan A . Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 2002; 105(5):602-7. DOI: 10.1161/hc0502.103363. View

Ma H, Guo P, Li J, Lin S, Chiang Y, Xiao X . Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res. 2002; 62(3):756-63. View

Ma H, Lin S, Chiang Y, Li J, Chen S, Tsao Y . Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther. 2002; 9(1):2-11. DOI: 10.1038/sj.gt.3301616. View

Muzyczka N . Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992; 158:97-129. DOI: 10.1007/978-3-642-75608-5_5. View

Kotin R, Linden R, Berns K . Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 1992; 11(13):5071-8. PMC: 556985. DOI: 10.1002/j.1460-2075.1992.tb05614.x. View

Chapman M, Rossmann M . Structure, sequence, and function correlations among parvoviruses. Virology. 1993; 194(2):491-508. DOI: 10.1006/viro.1993.1288. View

Ried M, Girod A, Leike K, Buning H, Hallek M . Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J Virol. 2002; 76(9):4559-66. PMC: 155067. DOI: 10.1128/jvi.76.9.4559-4566.2002. View

Girod A, Wobus C, Zadori Z, Ried M, Leike K, Tijssen P . The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol. 2002; 83(Pt 5):973-978. DOI: 10.1099/0022-1317-83-5-973. View

Fraites Jr T, Schleissing M, Shanely R, Walter G, Cloutier D, Zolotukhin I . Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther. 2002; 5(5 Pt 1):571-8. DOI: 10.1006/mthe.2002.0580. View

10.

Rolling F, Samulski R . AAV as a viral vector for human gene therapy. Generation of recombinant virus. Mol Biotechnol. 1995; 3(1):9-15. DOI: 10.1007/BF02821330. View

11.

Fisher K, Gao G, Weitzman M, Dematteo R, Burda J, Wilson J . Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol. 1996; 70(1):520-32. PMC: 189840. DOI: 10.1128/JVI.70.1.520-532.1996. View

12.

Ferrari F, Samulski T, Shenk T, Samulski R . Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996; 70(5):3227-34. PMC: 190186. DOI: 10.1128/JVI.70.5.3227-3234.1996. View

13.

Buning H, Ried M, Perabo L, Gerner F, Huttner N, Enssle J . Receptor targeting of adeno-associated virus vectors. Gene Ther. 2003; 10(14):1142-51. DOI: 10.1038/sj.gt.3301976. View

14.

Perabo L, Buning H, Kofler D, Ried M, Girod A, Wendtner C . In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther. 2003; 8(1):151-7. DOI: 10.1016/s1525-0016(03)00123-0. View

15.

Haberman R, Samulski R, McCown T . Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med. 2003; 9(8):1076-80. DOI: 10.1038/nm901. View

16.

Schlichtenbrede F, da Cruz L, Stephens C, Smith A, Georgiadis A, Thrasher A . Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy. J Gene Med. 2003; 5(9):757-64. DOI: 10.1002/jgm.401. View

17.

Muller O, Kaul F, Weitzman M, Pasqualini R, Arap W, Kleinschmidt J . Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol. 2003; 21(9):1040-6. DOI: 10.1038/nbt856. View

18.

Vassalli G, Bueler H, Dudler J, von Segesser L, Kappenberger L . Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol. 2003; 90(2-3):229-38. DOI: 10.1016/s0167-5273(02)00554-5. View

19.

Shi W, Arnold G, Bartlett J . Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther. 2001; 12(14):1697-711. DOI: 10.1089/104303401750476212. View

20.

Sanchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz K . Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther. 2001; 4(4):324-30. DOI: 10.1006/mthe.2001.0466. View